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Purpose: In male patients with congenital adrenal hyperplasia (CAH), the presence 
of testicular adrenal rest tumors (TARTs) have been reported, however their pre­
valence and clinical manifestations are not well known. Untreated TARTs may lead 
to testicular structural damage and infertility. This study was conducted to investi­
gate the prevalence of TARTs in male patients with CAH, and characterize the mani­
festations to identify contributing factors to TART.
Methods: Among 102 CAH patients aged 0–30 years, 24 male patients have been 
regularly followed up in our outpatient clinic at Severance Children’s Hospital from 
January 2000 to December 2014. In order to reveiw the characteristics of TART 
patients, we calculated the mean levels of hormones during the 5 years before the 
time of investigation. Five patients underwent follow­up scrotal ultrasonography 
(US) after adjusting the dosage of glucocorticoids.
Results: TARTs were detected in 8 of the 13 patients (61.5%). The median age of 
TARTs diagnosis was 20.2 years with the youngest case being 15.5 years old. The 
mean serum level of adrenocorticotropic hormone (ACTH) was higher in the TARTs 
patient group compared to the non­TARTs group (P<0.05). The tumor size decreased 
in 3 cases, slightly increased in 1 case, and had no change in another case.
Conclusion: The serum ACTH level might be associated with the growth promoting 
factor for TARTs, but the exact mechanism has not been clearly identified. Screening 
for TARTs using US is important in male patients with CAH for early­detection and 
prevention of ongoing complications, such as infertility.
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Introduction
Congenital adrenal hyperplasia (CAH) is a common endocrine disease whose incidence 
ranges from 1:10,000 to 1:20,000 births1), and is passed on in an autosomal recessive 
pattern2,3). It is caused by a defect in adrenal steroid synthesis, with more than 90% of cases 
being caused by 21-hydroxylase deficiency (21-OHD). The 21-OHD induces glucocorticoid 
and mineralocorticoid deficiency, the lack of which leads to a compensatory increase 
in adrenocorticotropic hormone (ACTH) secretion. This, in turn, causes adrenal gland 
hyperplasia and overproduction of the adrenal androgens. The 21-OHD is divided into salt 
wasting (SW) type and simple virilizing (SV) type, according to the with electrolyte imbalance 
and depending on the severity of the enzyme defect3). 
In male CAH patients, one of the most important complications is infertility. Many 
explanations for the infertility have been proposed; however, testicular adrenal rest tumors 
(TARTs) are known to be the most important cause of infertility in these patients4-6). TARTs 
were first described in 1940 by Wilkins et al. (quoted from 7)), and many case reports have 
been published subsequently8). The prevalence of TARTs in CAH patients has not been 
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clearly established yet. Previous studies have showed that the 
prevalence varies from 0%–94%6,9-11), depending on patient 
selection (age and hormonal control) and tumor detection 
methods (palpation, ultrasonography [US], or magnetic 
resonance imaging)12). 
The etiology and contributing factors of the tumors were not 
determined, however some hypotheses have been suggested. 
Adrenal tissue remnants in the testis can be observed in normal 
neonates (7.5%–15%), with most cases regressing during 
infancy13-16). However, in patients with CAH, chronically 
elevated ACTH may block regression of the adrenal tissue 
remnants and induce hyperplasia, eventually resulting in 
tumor development17). Although this is one possible hypothesis 
regarding TART development, the exact etiology has not been 
fully explained.
TARTs can compress the adjacent testicular tissues, which 
induces seminal tubule obstruction, resulting in oligospermato-
genesis6,9). It is a proven risk factor for infertility, and develop-
ment of tumor and increase in tumor size may start in child-
hood17,18). Therefore, early screening and diagnosis of TARTs, 
with appropriate treatment, are important for protection against 
gonadal failure and infertility19). 
This study was conducted to determine the prevalence of 
TARTs in our group of male CAH patients using scrotal US, and 
to define the factors that contribute to TART development by 
comparing the laboratory findings and clinical presentations 
of TART and non-TART patients. Furthermore, we compared 
the follow-up results of scrotal US among the TARTs patients in 
order to determine any associations between dose adjustment 
of hydrocortisone treatment and changes in tumor size.
Materials and methods
Among 102 patients aged 0–30 years old diagnosed as 
CAH, 24 male patients have been regularly followed up in our 
outpatient endocrine clinic at Severance Children’s Hospital 
from January 2000 to December 2014. In all patients, the 
diagnosis was based on symptoms and laboratory tests, and 
in some patients, molecular genetic analysis of 21-OHD was 
performed. Among the 24 patients, 13 underwent scrotal US. 
We retrospectively reviewed the medical records; basic 
anthropometric measurements (height, weight, and body 
mass index); and biochemical parameters, such as serum 
17-hydroxyprogesterone (17-OHP), ACTH, renin activity, 
and testosterone. The follow-up interval of the patients in our 
outpatient clinic was 3 months, and physical examination and 
laboratory tests were performed at each visit. Pubertal status 
was estimated according to Tanner staging, and the Prader 
orchidometer was used for measuring testicular volume20). The 
hormonal levels were estimated at a consistent time before 
the patients taking the morning medications. The serum 
hormone levels were estimated on the basis of the serum 17-
OHP (normal range, 0.59–3.44 ng/mL), ACTH (normal range, 
7.2–63.3 pg/mL), renin activity (normal range 1.31–3.95 ng/
mL/hr), and testosterone (normal range, 249–836 ng/dL in 
Tanner stage 5) levels. Serum ACTH levels were measured by 
electrochemiluminescence immunoassay and the Cobas e411 
analyzer using the Roche kit. Serum 17-OHP and renin activities 
were measured using the enzyme-linked immunosorbent assay 
kit (DRG instruments GmbH, Marburg, Germany). Serum 
testosterone levels were measured by the chemiluminescent 
microparticle immunoassay method on an Architect i2000 
analyzer using the Architect/Abbott kit. All patients were treated 
with hydrocortisone 2–3 times a day. In patients with the SW 
type, fludrocortisone was added to the treatment regimen. We 
defined the adequate control of CAH as serum 17-OHP and 
ACTH levels less than 10 ng/mL and 70 pg/mL, respectively21).
Scrotal US was chosen for the diagnosis of  TARTs in 
CAH patients, because it is a cheap, noninvasive, and easily 
accessible method9,22). All US evaluations were performed in 
our hospital by radiologists with extensive experience. High-
resolution ultrasound (Acuson Sequoia 512, Siemens Medical 
Solutions USA, Mountain View, CA, USA, or LOGIQ 9, General 
Electronics Company, Milwaukee, WS, USA) and a 12- to 15-
MHz linear probe were used for this evaluation. The diameter 
of TARTs was assessed in at least two dimensions (transverse 
and longitudinal) by caliper. The diagnosis was confirmed when 
the scrotal US demonstrated heterogeneous, hypoechogenic 
areas surrounding the echogenic testis mediastinum with 
welldefined margins10,16,23,24). In 2009, Claahsen-van der Grinten 
et al.12) suggested a staging system for TARTs. We classified the 
tumors into five different stages according to this staging system. 
Stage 1 is the presence of adrenal rest cells within the rete testis, 
not detectable by scrotal US. Stage 2 means the adrenal rests 
cells might be visible on US. Stage 3 means further growth of 
the adrenal rest cells with compression of the rete testis. Stage 
4 means further hypertrophy and hyperplasia of the adrenal 
rest cells with progressive obstruction of the rete testis with 
induction of fibrosis and focal lymphocytic infiltrates. Stage 
5 means chronic obstruction and irreversible damage of the 
testicular parenchyma.
In order to compare the characteristics of TART patients with 
non-TART patients, we calculated the mean levels of the above 
hormones during the 5 years before the time of investigation. 
The renin activity was not included since these were not 
measured in patients with the SV type. Differences of the clinical 
and biochemical parameters between the two groups that were 
classified according to the existence of TARTs were assessed by 
the Mann-Whitney U-test. The IBM SPSS Statistics ver. 20.0 
(IBM Co., Armonk, NY, USA) was used to analyze each outcome 
measured. P-values of <0.05 were considered significant.
Results
Among the 24 male CAH patients, scrotal US was performed 
in 13 patients. All of the patients were diagnosed with the classic 
form of CAH due to 21-OHD. Eight of the 13 patients had 
the SW type, while 5 had the SV type of CAH. The 13 patients 
were all in Tanner 5 pubertal stage with a median age of 20.5 
years (range, 15.5–29.4 years). The clinical characteristics and 
157
Yu MK, et al. • Testicular adrenal rest tumor in congenital adrenal hyperplasia 
www.e­apem.org
laboratory results of the patients who had scrotal US are listed 
in Table 1. Patients with the SW type were all diagnosed as CAH 
during the neonatal or infancy period. The patients with the SV 
type were diagnosed between 1 and 15 years of age. None of the 
patients were suspected as TART clinically before performing 
the scrotal US, indicating that all patients demonstrated no 
remarkable findings on physical examination.
TARTs were detected in 8 of the 13 patients (61.5%). The 
median age at which TARTs were diagnosed was 20.2 years 
with the youngest case being 15.5 years old. The prevalence of 
the SW type (6 of the 8 patients, 75%) and SV type (2 of the 5 
patients, 40%) of TARTs did not differ significantly. Regarding 
the results of molecular studies performed on 2 patients with 
TARTs, case 1 was homozygous for p.Ile172Asn mutation while 
case 2 was homozygous for the c.293-13C>G mutation. We 
considered serum 17-OHP or ACTH levels above 10 ng/mL or 
70 pg/mL, respectively, as representative of uncontrolled disease. 
There were 6 (out of 8, 75%) and 1 (out of 5, 20%) patients with 
uncontrolled disease in the TARTs and non-TARTs patient 
groups, respectively. 
We tried to compare the overall clinical characteristics and 
the extent of hormonal controls between the TARTs and non-
TARTs patient groups. The result is listed in Table 2. The median 
dose of hydrocortisone equivalent during the 5 years before 
conducting the first scrotal US was 21.1 mg/m2 and 22.2 mg/
m2 in the TARTs and non-TARTs patient groups, respectively, 
which were not statistically significant. The mean serum 17-
OHP, ACTH, and testosterone levels during the 5 years before 
Table 1. A comparison of the individual clinical characteristics and laboratory results of CAH patients with and without TARTs
Case Type of CAH
Age at
diagnosis of 
CAH (yr)
TARTs on
scrotal US
(R/L)
Age at 1st 
scrotal US 
(yr)
Age at 
diagnosis of 
TARTs (yr)
Tanner
stage
Serum hormone levels
(at the time of scrotal US)
Genotype Allel1/Allel2
ACTH
(pg/mL)
17-OHP
(ng/mL)
Renin 
activity
(ng/mL/hr)
Testosterone 
(ng/dL)
Patients with TARTs
  1 21-OHD.SV 7.2 -/+ 18.5 18.5 5 328.5 74.30 5.95 386 p.Ile172Asn/p.Ile172Asn
  2 21-OHD, SV 15.6 +/+ 21.0 21.0 5 1,344 103.9 10.12 405.9 c.293-13C>G/c.293-13C>G
  3 21-OHD, SW Neonatal +/- 20.5 20.5 5 36.15 4.68 3.67 487.5 N/A
  4 21-OHD, SW Neonatal +/+ 24.1 24.1 5 128.7 26.1 15.28 51.5 N/A
  5 21-OHD, SW Neonatal +/+ 20.7 20.7 5 271.5 83.8 6.71 702 N/A
  6 21-OHD, SW 0.8 +/+ 19.8 19.8 5 7.34 3.50 >37 350.9 N/A
  7 21-OHD, SW Neonatal +/+ 15.9 15.9 5 8.86 8.85 32.01 317.1 N/A
  8 21-OHD, SW Neonatal +/+ 15.5 15.5 5 2.47 0.37 0.20 205.3 N/A
Patients without TARTs
  9 21-OHD, SV 3.5 -/- 29.4 - 5 66.74 17.72 12.52 273.8 N/A
  10 21-OHD, SV 6.5 -/- 17.0 - 5 15.18 8.38 14.07 505.4 N/A
  11 21-OHD, SV 8.8 -/- 18.2 - 5 2.12 6.94 31.39 148 N/A
  12 21-OHD, SW Neonatal -/- 20.5 - 5 522.2 12.42 0.76 162.6 N/A
  13 21-OHD, SW 0.2 -/- 20.7 - 5 9.84 1.97 22.13 623.4 Intron 2 splice mutation/
Intron 2 splice mutation
CAH, congenital adrenal hyperplasia; TART, testicular adrenal rest tumor; US, ultrasonography; ACTH, adrenocorticotrophic hormone; 17-
OHP, 17-hydroxyprogesterone; 21-OHD, 21-hydroxlyase deficiency; SV, simple virilizing; SW, salt wasting; N/A, not applicable.
Table 2. A comparison of the clinical and biochemical parameters of CAH patients with and without TARTs
Variable TARTs patients (n=8) Non-TARTs patients (n=5) P-value
Age at scrotal US (yr) 20.2 (15.5–24.1) 20.5 (17.0–29.4) 0.769
Height (cm)  164.0 (146.0–179.0)   164.6 (157.5–169.0) 0.608
Weight (kg)  62.0 (46.0–117.0) 70.8 (52.0–82.0) 0.942
BSA (m2) 1.68 (1.37–2.33) 1.78 (1.54–1.96) 0.826
Hydrocortisone equivalent dose (mg/m2)a) 21.1 (14.6–24.7) 22.2 (19.5–33.7) 0.272
ACTH (pg/mL)a) 144.6 (39.0–514.8) 36.5 (6.4–111.5) 0.040
17-OHP (ng/mL)a) 12.3 (7.6–105.2) 6.9 (1.6–13.8) 0.079
Testosterone (ng/dL)a)   260.1 (181.1–611.6)   254.0 (157.0–589.0) 0.884
Values are presented as median (range).
P-values were determined using the Mann-Whitney U-test for continuous variables.
CAH, congenital adrenal hyperplasia; TART, testicular adrenal rest tumor; US, ultrasonography; BSA, body surface area; ACTH, adrenocorticotrophic 
hormone; 17-OHP, 17-hydroxyprogesterone.
a)The hydrocortisone dose as well as the serum ACTH, 17-OHP, and testosterone levels represent the mean of the values in the immediate 5 years prior 
to the first scrotal US.
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conducting the first scrotal US were also estimated. There were 
no clear differences in other laboratory values except for the 
mean serum ACTH level, which was higher in the TART group 
than the non-TARTs group (P<0.05). The median value was 
144.6 pg/mL (range, 39.0–514.8 pg/mL) in patients with TARTs, 
and 36.5 pg/mL (range, 6.4–111.5 pg/mL) in patients without 
TARTs.
The transverse and longitudinal diameters of the TART 
measured by the scrotal US and the follow-up results are 
compared in Table 3. TARTs were bilateral in 6 out of the 8 
patients (75%). All patients with TARTs were in stage 2, which 
indicates hypertrophy and hyperplasia of the adrenal rest cells 
without compression of the rete testis. The patients were all 
treated with hydrocortisone (median, 21.1 mg/m2 per day). In 
patients with SW type, fludrocortisone (0.1 mg/day) was added 
to the treatment regimen. In 4 out of the 8 patients (cases 3, 6, 7 
and 8), we maintained the treatment of hydrocortisone for the 
same dose before and after the diagnosis of TARTs. In contrast, 
the hydrocortisone doses of the 4 other patients (cases 1, 2, 4, 
and 5) were increased after detection of the tumor, which was 
based on the therapeutic control of the hormonal status. Among 
the 8 patients with TARTs, 5 patients had follow-up scrotal 
US, and the follow-up duration was from 6 months to 1 year. 
The tumor size decreased in 3 cases (cases 5, 6, and 8), slightly 
increased in 1 case (case 7), and had no interval changes in 
another case (case 3). Among the 3 patients whose tumor size 
decreased, 1 patient received a higher dose of hydrocortisone 
for therapeutic control (19.5 mg/m2 before diagnosis, and 26.0 
mg/m2 after diagnosis) while the other 2 patients maintained the 
same dose of the medication. There seems to be no significant 
association between the dose adjustment of the hydrocortisone 
and the changes in tumor size. Regardless of the treatment 
dose adjustment, the patients with decreased tumor size all 
demonstrated significantly decreased ACTH levels compared to 
the baseline study (317.0–29.1 pg/mL in case 5; 89.4–6.5 pg/mL 
in case 6; and 42.6–6.0 pg/mL in case 8). In contrast, 1 patient 
(case 7) with increased tumor size did not show a significant 
decrease in the serum ACTH level (39.0–30.8 pg/mL).
Surgical biopsy was performed in 1 case (case 2). This patient 
was diagnosed with the SV type of CAH at 15.6 years old. 
Abdominopelvic computed tomography scan was performed 
because of a car accident, and he was incidentally diagnosed 
with adrenal cortical carcinoma. He underwent resection 
surgery of the left adrenal gland when he was 16 years old, and 
was treated with hydrocortisone 14.59 mg/m2 daily. Five years 
later, he had scrotal US for TARTs screening, and was diagnosed 
as TART. Because the US result could not rule out the possibility 
of tumor metastasis, biopsy of the scrotal mass was performed 
in this case. The results of the pathologic exam were consistent 
with TARTs and inhibin-alpha was positive in the tumor cells 
on immunohistochemical staining, suggesting the cells were of 
adrenal cortical origin.
Discussion
The prevalence of TARTs in males with CAH was 61.5% in 
this study. Several previous studies showed variable prevalence 
(0%–94%)6,9-11) in various study populations, including child-
hood, adolescence and adulthood. Higher prevalence was found 
in studies involving adult patients, whereas a lower prevalence 
was reported in the studies involving younger patients5,25). 
Compared to the previous studies, the relatively higher 
TART prevalence in this study may be due to the advanced 
pubertal stage in the patients who had scrotal US. The patients 
Table 3. A comparison of tumor sizes and stages, mean serum ACTH levels, and steroid treatment doses among CAH patients with TARTs, 
at the time of diagnosis and in the follow-up period (6 months or 1 year)
Case
At diagnosis Follow-up
Mass
size change
F/U
period 
(mo)
Diameter at
diagnosis
(mm)
Tumor
stage
Mean
ACTH
levela)
Hydrocortisone 
dose (mg/m2)
Fludrocortisone 
dose (mg/day)
Diameter 
at
follow-up
(mm)
Tumor 
stage
Mean
ACTH 
Levelb)
Hydrocortisone 
dose (mg/m2)
Fludrocortisone 
dose (mg/day)
1 4×5 (L) 2 185.5 24.7 - - 2 92.2 30.9 - - -
2 27×27 (R)/
23×31 (L)
2 514.8 14.6 - - 2 176.5 29.2 - - -
3 4×8 (R) 2 103.7 24.4 0.1 4×8 (R) 2 22.2 Same 0.1 No change 12
4 11×15 (R)/
18×20 (L)
2 340.5 17.2 0.1 - 2 212.0 21.5 0.1 - -
5 25×15 (R)/
23×10 (L)
2 317.0 19.5 0.1 15×10 (R)/
15×8 (L)
2 29.1 26 0.1 Decreased 12
6 38×16 (R)/
28×20 (L)
2 89.4 18.4 0.1 20×13 (R)/
22×16 (L)
2 6.5 Same 0.1 Decreased 12
7 10×15 (R)/
10×18 (L)
2 39.0 23.3 0.1 15×15 (R)/
10×20 (L)
2 30.8 Same 0.1 Slightly 
increased
6
8 25×30 (R)/
23×33 (L)
2 42.6 22.7 0.1 25×30 (R)/
15×23 (L)
2 6.0 Same 0.1 Decreased 10
ACTH, adrenocorticotrophic hormone; CAH, congenital adrenal hyperplasia; TART, testicular adrenal rest tumor. 
a)The average value of serum ACTH levels for 5 years before diagnosis of TART. b)The average value of serum ACTH levels for 6 months to 1 
year during the follow-up period.
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involved in our study were all in the Tanner 5 pubertal stage. 
The youngest patient with TART was 15.5 years old and was 
diagnosed with TART at his first US screening. Thus, we gave 
attention about the existence of tumor before conducting the 
scrotal US. The youngest CAH patient with TART reported in 
the literature was only several weeks old26). Therefore, to find 
a more precise prevalence, earlier detection of tumor with US 
screening in male CAH patients, and longitudinal study for a 
longer period of time is needed.
It has been proven that TARTs consist of cells with clear 
features of adrenocortical tissue27-29). However, the etiology and 
growth promoting factors of TARTs are still unclear, making 
it difficult to define the steps necessary for preventing tumor 
growth25). In the majority of the reported studies, patients with 
TARTs had poor metabolic control30,31), and uncontrolled 
hormonal status, which is believed to be one of the important 
causes in the pathogenesis of TARTs. Among the hormones, 
ACTH is the most frequently suggested causative and growth 
promoting factor in TARTs27,32). However, there is some 
controversy regarding this hypothesis, since TARTs are also 
diagnosed in adequately treated children and may not develop 
in adult male CAH patients with poorly controlled disease27). 
In our study, the median value of the 5-year mean ACTH level 
in the TARTs group was significantly higher than in the non-
TARTs group. In addition, according to the follow-up results, 
the 3 patients whose tumor size decreased showed markedly 
lower serum ACTH levels. Therefore, we can support the 
previous hypothesis that exposure to high concentrations of the 
serum ACTH level can be a major factor in the development of 
TARTs. This hypothesis could be taken into consideration for 
the treatment of TARTs. In addition, monitoring and education 
for good adherence to medication are very important, especially 
in adolescent and adult patients. In our study, even though more 
than usual dosages of hydrocortisone were prescribed, mean 
ACTH levels were higher than the normal range, suggesting 
poor adherence. 
There are several studies concerning other contributing fac-
tors of TART, and some results reported luteinizing hormone 
could be a contributing factor33). Recently, studies have shown 
that the tumor growth in patients with CAH may not only be 
stimulated by ACTH, but also by elevated angiotensin II level15). 
However, in this study, the reviewed hormonal parameters (17-
OHP, testosterone) except for ACTH and the mean levels of 
hydrocortisone doses between the two patient groups did not 
show any significant differences. To find other contributing 
factors of TARTs, further investigations must be explored in 
larger populations.
The treatment of TARTs has not been well defined thus far. 
Several studies suggested that intensifying hydrocortisone 
therapy might lead to a reduction in tumor size by suppression 
of ACTH secretion18). However, adequate ACTH suppression 
with high-dose hydrocortisone treatment was not always 
successful in reducing the tumor size6,19,34). In our follow-
up results, there were no significant differences in tumor size 
associated with the hydrocortisone dose. Nevertheless, the 
serum ACTH level demonstrated remarkable decline in patients 
with decreased tumor size. Although some case reports35,36) have 
reported a reduction in the size of TARTs after a higher dose 
of hydrocortisone treatment, which recurred after decreasing 
the dose, we cannot make a conclusion from this limited obser-
vation. In order to clarify the treatment methods for TARTs, 
studies involving larger patient populations who will be 
followed for longer time periods, will need to be explored.
Since TARTs do not have malignant features, there is no 
need to treat or remove the tumors at an early stage. Surgical 
removal of  the tumor is recommended when the tumor 
has advanced beyond stage 332,37). However, because of the 
localization to the rete testis regardless of the size, TARTs may 
compress the seminiferous tubules leading to obstruction 
and irreversible damage25,34,37). Therefore, early detection and 
proper management of TARTs are important before the onset 
of permanent damage11). Previous studies recommend semen 
analysis and spermatograms with subsequent cryopreservation, 
if  needed, in order to improve fertility in patients with 
TARTs26,30). In our study, patients with TARTs were all in tumor 
stage 2 and did not undergo semen analysis due to their early 
tumor stage. Since the analysis was not performed, the impact 
of TARTs on infertility cannot be established in this study. 
However, considering the long term preservation of fertility in 
TARTs patients, we are planning to have semen analysis from 
early stage of the tumor.
As a screening tool, scrotal US offers many advantages inclu-
ding low cost, technical simplicity, and non-invasiveness24). The 
minimum testicular tumor size that was detected by scrotal 
US is approximately 2 mm in diameter24). In our study, none 
of the tumors were detected by physical examination and 
none of the patients with TARTs complained of symptoms 
of gonadal dysfunction at the time of diagnosis. As a scrotal 
US offers efficient screening modality and TARTs are usually 
asymptomatic, it is important for the TART patients to 
have scrotal US before presenting any gonadal symptoms. 
Claahsen-van der Grinten et al.12) proposed that screening for 
TARTs in male CAH patient should start at 8 years old. Other 
studies22,38,39) have suggested initiating scrotal US screening 
during the pubertal period. Therefore, scrotal US screening 
must be performed at least before puberty and regularly during 
adulthood in male CAH patients in order to prevent infertility. 
Also, regular screening by scrotal US should be performed 
at least every 2 years in early childhood and annually in the 
peripubertal period18). 
In conclusion, the prevalence of TARTs was 61.5% in our 
group of male patients with CAH. Based on our results, the 
serum ACTH level might be associated with the growth 
promoting factor for TARTs; however, the exact mechanism 
of progression and regression has not been clearly identified. 
Although no significant differences in tumor size were identified 
according to hydrocortisone dose, studies involving larger 
patient populations who are followed for longer periods of time 
are necessary in order to clarify the treatment of TARTs. Since 
all the patients with TARTs in our study did not have palpable 
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and clinically detectable tumors, it is very important for scrotal 
US screening to be initiated before puberty. Scrotal US should 
be followed up every 1–2 years because of the possibility of 
increases in tumor size and the risk of infertility.
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